

August 14, 2019

Corporate Relationship Department
BSE Limited
Dalal Street, Fort
Mumbai – 400 001
Fax Nos.: 022-22723121 / 22723719 /
22722037 / 22722039

National Stock Exchange of India Ltd.
“Exchange Plaza”
Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 051
Fax Nos.: 022-26598120/ 26598237/
26598238

Scrip Code: 500124

Scrip Code: DRREDDY-EQ

Dear Sirs,

Ref.: Your email dated August 14, 2019

Sub: Clarification/Confirmation on news item appearing in - www.bloomberqqint.com,
captioned "Setback for Dr. Reddy's as U.S.FDA hands out complete response letter for NuvaRing"

This is with reference to your email dated August 14, 2019, seeking clarification on the above subject.

In this regard, please note that our investor deck was updated on our website yesterday, wherein we have stated that the Company has received a Complete Response Letter (CRL) from USFDA and is preparing its response to the USFDA.

We would also like to mention that receiving a CRL is in the ordinary course of the Company's business and hence we do not have a practice of disclosing any CRL from USFDA on any product.

However, during our earnings call held on July 29, 2019, we informed the investors of possible queries from USFDA on NuvaRing.

This is for your information and record.

With regards,


Sandeep Poddar
Company Secretary